Home / Business and Economy / HRV Pharma Bets Big on Peptides & Oncology
HRV Pharma Bets Big on Peptides & Oncology
7 Sep
Summary
- HRV Pharma invests ₹150 crore in dedicated peptides and oncology capacity.
- Partnership with Arene Lifesciences for a dedicated peptide facility.
- Company focuses on owning IP and outsourcing manufacturing to remain asset-light.
Hyderabad-based HRV Pharma is making a significant strategic pivot, investing around ₹150 crore to bolster its specialized manufacturing capacity in peptides and oncology. This move represents a departure from its prior model of utilizing existing manufacturing capabilities.
Instead, HRV Pharma will focus on underwriting dedicated capacity for products it owns, including the intellectual property and regulatory rights. The company is partnering with Arene Lifesciences for a ₹50 crore investment in a dedicated peptide facility. Furthermore, HRV Pharma is allocating ₹100 crore for a high-potency oncology API manufacturing facility, expected to be announced soon.
This new strategy, described as "inverting" the traditional approach, allows HRV Pharma to control IP and customer relationships while acting as a CDMO client for manufacturing partners. The peptide business is projected to start contributing to financial performance by fiscal year 2028, with an estimated $2 billion addressable market in regulated regions.
HRV Pharma anticipates its revenue to surpass ₹600 crore in FY27, with the United States anticipated to be a major growth driver. The company is also exploring international acquisitions while deliberately avoiding direct investment in physical manufacturing assets.
